Transgenic mouse models with nicotinic acetylcholine receptor (nAChR) knockouts and knockins have provided important insights into the molecular substrates of addiction and disease. However, most studies of heterologously expressed neuronal nAChR have used clones obtained from other species, usually human or rat. In this work, we use mouse clones expressed in Xenopus oocytes to provide a relatively comprehensive characterization of the three primary classes of nAChR: muscle-type receptors, heteromeric neuronal receptors, and homomeric ␣7-type receptors. We evaluated the activation of these receptor subtypes with acetylcholine and cytisine-related compounds, including varenicline. We also characterized the activity of classic nAChR antagonists, confirming the utility of mecamylamine and dihydro-␤-erythroidine as selective antagonists in mouse models of ␣3␤4 and ␣4␤2 receptors, respectively. We also conducted an in-depth analysis of decamethonium and hexamethonium on muscle and neuronal receptor subtypes. Our data indicate that, as with receptors cloned from other species, pairwise expression of neuronal ␣ and ␤ subunits in oocytes generates heterogeneous populations of receptors, most likely caused by variations in subunit stoichiometry. Coexpression of the mouse ␣5 subunit had varying effects, depending on the other subunits expressed. The properties of cytisine-related compounds are similar for mouse, rat, and human nAChR, except that varenicline produced greater residual inhibition of mouse ␣4␤2 receptors than with human receptors. We confirm that decamethonium is a partial agonist, selective for muscle-type receptors, but also note that it is a nondepolarizing antagonist for neuronal-type receptors. Hexamethonium was a relatively nonselective antagonist with mixed competitive and noncompetitive activity.
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Biomedical research is motivated largely by the desire to understand human diseases and develop therapeutic approaches for the treatment of those diseases. To those ends, animal models are frequently used, to both understand basic biology and determine the pharmacological potential of new drugs. In recent decades, research with in vivo animal models and acute ex vivo preparations has been supplemented, and in some cases largely replaced, by in vitro approaches, such as tissue culture models or heterologous expression systems. Both tissue culture and heterologous expression offer the advantage that the cells or molecules studied may be human in origin, obviating the concern that there may be species differences in the effects of drugs intended for human therapeutics. However, neither tissue culture nor heterologous expression systems are likely to provide adequate context to model disease states. Disease models still most often require whole-animal studies.
In the past 50 years biomedical research has relied primarily on rodent models, with the rat representing the most common rodent model. However, the number of mouse studies relative to rat studies has increased significantly since 1980, because the recent genesis of valuable transgenic mouse lines has provided important new disease models (Marubio and Changeux, 2000) .
Transgenic mice have been very useful for nicotinic receptor research (Marubio and Changeux, 2000) , with multiple strains of knockout mice allowing us to ask important probative questions regarding the molecular substrates of nicotine addiction and the appropriate molecular targets for potential therapeutics (Champtiaux and Changeux, 2004) . Ironically, although one would expect that studies with knockout animals would go hand in glove with studies of heterologously expressed receptors, most studies of heterologously expressed neuronal nAChR have used cDNAs cloned from rats, humans, or chickens (Hussy et al., 1994; Zwart et al., 2006; Papke et al., 2008) . Very few studies of neuronal nAChR have used mouse receptor clones, although many studies of muscle-type nAChR have used the embryonic form of the mouse receptor, because of the early cloning of those genes from the BC 3 H1 cell line (Patrick et al., 1987) .
There are three broad classes of nAChR subtypes, all of which can function as ligand-gated cation channels (Millar and Gotti, 2009 ). The first nAChRs to be isolated and well studied were those expressed by muscle cells. They are pentamers with the subunit composition ␣1␤1␥␦ in embryonic muscle (with two ␣1 subunits in each pentamer). In adult muscle an ε subunit substitutes for the ␥. A second class of heteromeric nAChRs includes those expressed in neurons that contain specialized ␣ subunits (␣2, ␣3, ␣4, or ␣6) and non-␣ subunits (␤2 or ␤4), sometimes coexpressed with the accessory subunits ␣5 or ␤3. In the heteromeric receptors of autonomic (i.e., ganglionic) neurons the primary ␣ subunit is ␣3, whereas in the rodent central nervous system (CNS) the primary ␣ subunit is ␣4. The third class of nAChR is considered ancestral, because those nAChRs function as homopentamers with only ␣ subunits (usually ␣7). Such ␣7-type receptors are expressed by both neurons and some non-neuronal cell types, such as cells in the immune system (de Jonge and Ulloa, 2007) .
In the present study, we present an analysis of the acetylcholine (ACh)-evoked activation of the three classes of mouse nAChR. We also characterized the effects of the cytisine derivative varenicline (Rollema et al., 2007) , the most recently approved drug for the treatment of nicotine dependence, and compared its effects with the parent compound cytisine and the recently reported cytisine derivative 3-pyrCyt ) on important mouse neuronal nAChR subtypes. We further extend our studies to provide a comprehensive characterization of the putative neuromuscular blocker decamethonium (Paton and Zaimis, 1949) and the classical ganglionic blocker hexamethonium by using heterologously expressed mouse nAChR (Paton and Perry, 1953) .
Materials and Methods
Preparation of RNA. The mouse muscle ␣1, ␤1, ␥, and ␦ nAChR clones were obtained from Dr. Jim Boulter (University of California, Los Angeles, CA), and the mouse muscle ε clone was from Paul Gardner (University of Massachusetts Medical School, Worcester, MA). The human ␣4, ␤2, and ␣5 clones, and the ␤2-6-␣4 concatamer, were provided by Jon Lindstrom (University of Pennsylvania, Philadelphia, PA). The cDNAs for mouse ␣3, ␣4, ␣5, ␣7, ␤2, and ␤4 were cloned as reported previously (Stitzel et al., 1996 (Stitzel et al., , 2001 Azam et al., 2005) .
After linearization and purification of cloned cDNAs, RNA transcripts were prepared in vitro by using the appropriate mMessage mMachine kit from Ambion (Austin, TX).
Expression in Xenopus Oocytes. Mature (Ͼ9 cm) female Xenopus laevis African frogs (Nasco, Fort Atkinson, WI) were used as a source of oocytes. Before surgery, the frogs were anesthetized by placing the animal in a 1.5g/l solution of MS222 for 30 min. Oocytes were removed from an incision made in the abdomen.
To remove the follicular cell layer, harvested oocytes were treated with 1.25 mg/ml type 1 collagenase (Worthington Biochemicals, Freehold, NJ) for 2 h at room temperature in calcium-free Barth's solution [88 mM NaCl, 1 mM KCl, 0.33 mM MgSO 4 , 2.4 mM NaHCO 3 , 10 mM HEPES (pH 7.6), 12 mg/l tetracycline chloride]. Subsequently, stage 5 oocytes were isolated and injected with 50 nl (5-20 ng) of each of the appropriate subunit cRNAs. The RNAs injected for ␣␤ pairs were injected at a 1:1 ratio, and when ␣5 was included with an ␣␤ pair, the RNAs were injected at a 1:1:1 ratio. Recordings were made 1 to 10 days after injection.
Chemicals. Varenicline was provided by Targacept (Winston Salem, NC), and 3-pyr-Cyt ) was provided by Daniela Guendisch (University of Hawaii, Hilo, HI). All other chemicals for electrophysiology were obtained from Sigma-Aldrich (St. Louis, MO). Fresh ACh stock solutions were made daily in Ringer's solution and diluted.
Electrophysiology. Experiments were conducted by using OpusXpress 6000A (Molecular Devices, Sunnyvale, CA). OpusXpress is an integrated system that provides automated impalement and voltage clamp of up to eight oocytes in parallel. Cells were automatically perfused with bath solution, and agonist solutions were delivered from a 96-well plate. Both the voltage and current electrodes were filled with 3 M KCl. The agonist solutions were applied via disposable tips, which eliminated any possibility of cross-contamination. Drug applications alternated between ACh controls and experimental applications. Flow rates were set at 2 ml/min for experiments with ␣7 receptors and 4 ml/min for other subtypes. Cells were voltage-clamped at a holding potential of Ϫ60 mV. Data were collected at 50 Hz and filtered at 20 Hz. ACh applications were 12 s in duration followed by 181-s washout periods with ␣7 receptors and 8 s in duration with 241-s washout periods for other subtypes.
Measurement of Functional Responses. Pharmacological characterizations of ion channel responses often rely solely on the measurement of peak currents. However, with desensitizing receptors like nAChR, the peak amplitudes of agonist-evoked responses cannot be interpreted in any straightforward manner, because of their nonstationary nature. For heteromeric nAChR many factors determine peak current amplitudes, including agonist application rate, channel activation rates, desensitization, and even potentially channel block by agonist (Papke, 2009) . For ␣7 receptors, the peak currents are associated with synchronization of channel activation that occurs well in advance of the full agonist application (Papke and Papke, 2002) . Therefore, we have also measured and report the net charge of the responses to add insight into additional and important aspects of the functional responses.
Experimental Protocols and Data Analysis. Each oocyte received two initial control applications of ACh, then an experimental drug application and a follow-up control application of ACh. The specific control concentrations were chosen because they gave robust, reproducible responses that did not show significant rundown or cumulative desensitization with repeated applications. The control ACh concentrations for mouse ␣1␤1␥␦, ␣1␤1ε␦, ␣4␤2, ␣3␤2, ␣3␤4, ␣3␤2␣5, ␣3␤4␣5, ␣4␤2␣5, and ␣7 receptors were 30, 3, 10, 100, 100, 100, 100, 10, and 100 M, respectively. These concentrations represented the EC 90 , EC 4 , EC 20 , EC 50 , EC 60 , EC 25 , EC 60 , EC 20 , and EC 100 values for each of the receptors, respectively (measured for net charge for ␣7 and peak current for all others). For the human high-sensitivity (HS) ␣4␤2 [␣3(2)␤2(3)], low-sensitivity (LS) ␣4␤2 [␣3(3)␤2(2)], and ␣4␤2␣5 receptors, the control ACh concentrations were 10, 100, and 10 M, respectively. These represented the peak current EC 100 , EC 50 , and EC 60 values for each of the receptors, respectively.
Responses to each drug application were calculated relative to the preceding ACh control responses to normalize the data, compensating for the varying levels of channel expression among the oocytes. Drug responses were initially normalized to the ACh control response values and then adjusted to reflect the experimental drug responses relative to the ACh maximums. Responses were calculated as both the peak current amplitudes and net charge (Papke and Papke, 2002) . Means and standard errors were calculated from the normalized responses of at least four oocytes for each experimental concentration. Because the application of some experimental drugs cause the subsequent ACh control responses to be reduced because of some form of residual inhibition (or prolonged desensitization), subsequent control responses were compared with the preapplication control ACh responses. When cells failed to recover to at least 75% of the previous control they were discarded and new cells were used.
For concentration-response relations, data derived from net charge analyses were plotted by using Kaleidagraph 3.0.2 (Abelbeck Software, Reading, PA), and curves were generated from the Hill equation:
where I max denotes the maximal response for a particular agonist/subunit combination, and n represents the Hill coefficient. I max was constrained to equal 1 for the ACh responses, because we used the maximal ACh responses to define full agonist activity. Negative Hill slopes were applied for the calculation of IC 50 values associated with inhibition.
Results

ACh Activation
Shown in Fig. 1 are concentration-response studies for ACh activation of the two subtypes of mouse muscle nAChR, the adult form (␣1␤1ε␦) and the embryonic form (␣1␤1␥␦), ␣7 homopentamers, and the pairwise combinations of neuronal ␣ and ␤ subunits, ␣4␤2, ␣3␤4, and ␣3␤2. Data were analyzed for both peak currents and net charge. Because ACh is our reference agonist, for all plots in Fig. 1 , the I max was constrained to equal one.
For the adult muscle receptor, the ACh concentrationresponse curves (CRCs) were nearly overlapping, whereas for the embryonic form of the receptor the net charge curve was shifted to the right.
The mouse heteromeric neuronal nAChR showed a tendency toward having ACh CRCs that were best-fit by two components, consistent with the recent distinction made between HS and LS forms of ␣4␤2 nAChR of other species Moroni et al., 2006) and efflux studies with mouse brain tissues (Grady et al., 2009 ). Whereas ␣4␤2 receptors had nearly overlapping peak current and net charge response curves, the same was not true for the ␣3-containing receptors. The population of ␣3␤2 receptors with higher sensitivity to ACh seemed to contribute relatively little to the net charge concentration-response data. In contrast, putative HS ␣3␤4 receptors appeared to have small peak currents but contributed relatively large amounts of net charge. The EC 50 values for ACh activation of mouse nAChR are shown in Table 1 .
The Effects of Cytisine and Related Compounds
We evaluated the effects of cytisine and two cytisine derivatives, the antismoking drug varenicline (Coe et al., 2005) and the recently reported novel compound 3-pyr-Cyt ) on mouse neuronal nAChR. Peak current data are presented in Fig. 2 . Similar results were obtained with the analysis of net charge (not shown). As reported for other species (Table 2) , both cytisine and varenicline were effective activators of ␣3␤4 receptors ( Fig. 2A) , with cytisine being both the most potent and most efficacious of the two. Likewise, both varenicline and cytisine were relatively weak partial agonists of mouse ␣4␤2 nAChR, with maximal efficacies less than 15% that of ACh (Fig. 2B ). Like ACh, the cytisine responses of ␣4␤2 receptors were best-fit to a two-site model, whereas varenicline seemed to only work in a single concentration range, suggesting a potential selectivity for LS over HS ␣4␤2 receptors in mice.
Although with our standard 5-min washout period, the ACh responses of cells expressing mouse ␣4␤2 receptors recovered readily after the applications of cytisine throughout the concentration range studied, after the application of varenicline at concentrations Ն1 M, subsequent responses to ACh were greatly reduced in a concentration-dependent manner. This residual inhibition of mouse ␣4␤2 receptors was significantly greater than when varenicline was applied to cells expressing human ␣4␤2 receptors in the same manner (i.e., by expressing ␣4 and ␤2 cRNAs at a 1:1 ratio). This was determined by exposing cells expressing either mouse ␣4␤2 or human ␣4␤2 receptors to two applications of 30 M ACh before the application of varenicline, followed by further applications of 30 M ACh. After the application of 1 M varenicline, the peak current responses of mouse ␣4␤2 receptors were reduced to only 29 Ϯ 6% of the initial controls, whereas human ␣4␤2 receptor responses were significantly larger (p Ͻ 0.05), 61 Ϯ 7% of the initial controls (data not shown). In contrast, after the application of 10 M varenicline, the peak current responses of mouse ␣4␤2 receptors were further reduced to only 7 Ϯ 1% of the initial controls, whereas human ␣4␤2 receptor responses were significantly (p Ͻ 0.0001) larger, 44 Ϯ 22% of the initial controls. Similar differences were seen in the net charge measurements (not shown). These results suggest that the effects of varenicline may be similar to those of mouse and human nAChR during acute applications, but with prolonged treatments, varenicline may be more effective at down-regulating mouse ␣4␤2 nAChR than human ␣4␤2 nAChR.
As expected, both varenicline and cytisine were efficacious activators of mouse ␣7 receptors (Table 2 ; data not shown). Varenicline was a very potent full agonist at mouse ␣7 receptors, with an EC 50 of 0.8 M. However, the potency of cytisine for mouse ␣7 receptors was less than previously reported for rat and human ␣7 receptors (Table 2) .
Like what has been reported for human receptors, 3-pyrCyt was able to activate mouse ␣7 receptors at very high concentrations. When applied at 1 mM, it evoked a net charge response that was 40 Ϯ 15% of the ACh maximum. At this concentration, the peak currents were only approximately 12% the ACh maximum, indicative of very low potency activation. We estimate that although the efficacy of 3-pyr-Cyt, extrapolated to higher concentrations than we normally test, might be as high as 80 to 100% that of ACh, the EC 50 would be Ͼ3 mM, 40-fold higher than that of cytisine.
Neither cytisine nor the other two related compounds produced detectable levels of activation of mouse ␣3␤2 receptors (not shown). The cytisine derivative 3-pyr-Cyt was also ineffective at the other heteromeric mouse neuronal nAChR tested, as evidenced by no currents generated above our reliable level of detection (approximately 1% ACh maximum). Although 3-pyr-Cyt was not an effective activator of human ␣4␤2 receptors expressed in oocytes, it was able to inhibit ACh-evoked responses when coapplied with ACh. Similar results were obtained with mouse ␣4␤2 receptors (Fig. 2C) , with an inhibition of ACh-evoked responses approximately 6-fold more potent (Table 2) than Activation and Inhibition of Mouse nAChR Fig. 1 . Concentration-response studies for mouse muscle and neuronal nAChRs expressed in Xenopus oocytes. A, ␣1␤1ε␦. B, ␣1␤1␥␦. C, ␣7. D, ␣4␤2. E, ␣3␤4. F, ␣3␤2. Data were obtained by alternating applications of ACh at fixed control concentrations (see Materials and Methods) and ACh at increasing concentrations. The control responses were relatively consistent throughout the entire range of test concentrations. Test responses were initially normalized relative to the ACh controls, and the data are expressed relative to the observed ACh maximum responses. Data were calculated for both peak current and net charge as described (Papke and Papke, 2002) . Each point is the average Ϯ S.E.M. of responses from at least four oocytes.
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previously reported for human ␣4␤2 receptors ).
Effects of the Neuronal Nicotinic Antagonists Mecamylamine and Dihydro-␤-Erythroidine
Mecamylamine and dihydro-␤-erythroidine (DH␤E) are commonly used neuronal nAChR antagonists. Previous studies using rat nAChR clones (Papke et al., 2008) showed the noncompetitive antagonist mecamylamine to have a selectivity for rat ␤4-containing nAChR, whereas DH␤E, a competitive antagonist, was selective for ␣4-containing receptors (Papke et al., 2008) . To confirm whether this distinction would hold for mouse nAChR, we tested DH␤E and mecamylamine over a range of concentrations by using cells expressing mouse ␣3␤4 or ␣4␤2 receptors. As shown in Fig. 3 , the effects of DH␤E and mecamylamine on the mouse receptors compare well with previous results obtained with rat ␣4␤2 and ␣3␤4 nAChR. With the exception of DH␤E inhibition of ␣3␤4, the IC 50 values for the inhibition of net charge were lower than for peak current (Table 3 ). Our data indicate that DH␤E was 70-to 300-fold (based on inhibition of peak currents and net charge, respectively) more potent for the inhibition of ␣4␤2 receptors than for ␣3␤4 receptors, not unlike the 260-fold potency difference reported for the inhibition peak currents for rat ␣4␤2 relative to ␣3␤4 receptors (Papke et al., 2008) . Mecamylamine was 63-to 23-fold more potent for the inhibition of mouse ␣3␤4 receptors than for ␣4␤2 receptors (based on inhibition of peak currents and net charge, respectively), a potency difference much greater than the 9.2-fold difference reported for the inhibition of peak currents for the corresponding rat receptors (Papke et al., 2008) .
Effects of Decamethonium and Hexamethonium
Selective Partial Agonism of Muscle-Type nAChR by Decamethonium. Decamethonium has been reported to be a depolarizing blocker of the neuromuscular junction (Paton and Zaimis, 1949) . Therefore, we conducted concentrationresponse studies of the two forms of mouse muscle receptors to determine whether decamethonium was a partial agonist for these receptors (Fig. 4, A and B) . The data indicate that for ␣1␤1ε␦ receptors decamethonium has an efficacy approximately 10% that of ACh for peak currents and 15% that of ACh for net charge with EC 50 values of 40 Ϯ 3 and 86 Ϯ 10 M, respectively. For ␣1␤1␥␦ receptors, decamethonium has an efficacy approximately 8% that of ACh for peak currents and 5% for net charge with EC 50 values of 44 Ϯ 6 and 89 Ϯ Data without specific references were obtained as part of the current study.
1
The designations HS ␣4␤2 and LS ␣4␤2 indicate receptors with defined subunit composition formed by the coexpression of either ␣4 or ␤2 with linked ␣4 ␤2 concatamers. The designations ␣4␤2(HS) and ␣4␤2(LS) indicate that data were obtain from a mixed receptor populations that were best-fit with a two-site model.
2
Not determined, because a full concentration-response study was not conducted.
3
Likely an underestimate of potency because data are based on peak current rather than net charge.
4
Estimated as described previously (Papke, 2006) .
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8 M, respectively. Decamethonium did not evoke any detectable responses from any of the neuronal nAChR subtypes (data not shown).
The effects of decamethonium on ␣1␤1ε␦-expressing cells were studied in further detail (Fig. 4, C-F) . Figure 4 , C and D, shows plots of the responses to 3 M ACh plus decamethonium compared with the responses to decamethonium alone, normalized to ACh maximum responses. When increasing concentrations of decamethonium were coapplied with 3 M ACh to cells expressing mouse ␣1␤1ε␦ receptors, responses were obtained that were up to four to five times larger than the responses to 3 M ACh alone (3 M ACh being a relatively low effective concentration for the muscletype receptor). This was consistent with decamethonium acting as a partial agonist for the muscle-type receptor.
We also conducted ACh concentration-response studies in the presence of a fixed concentration (30 M) of decamethonium to confirm the competitive interactions between ACh and decamethonium (Fig. 4, E and F) . Interestingly, there was a more notable shift in the ACh EC 50 for peak currents than for net charge.
Antagonism of Neuronal nAChR by Decamethonium. We tested the effectiveness of decamethonium as an antagonist of mouse homomeric and neuronal nAChRs. The data indicate that decamethonium was equally potent for inhibition of peak and net charge for homomeric and all of the heteromeric neuronal nAChRs (Fig. 5) . Decamethonium was most potent as an antagonist of ␣7 receptors (Table 4 ). In addition, as shown in Fig. 5 , decamethonium was more potent as an antagonist of ␣4␤2 and ␣3␤4 nAChRs than for ␣3␤2 nAChRs. This is somewhat curious because antagonist sensitivity frequently can be related to the presence or absence of single subunits (Papke et al., 2008) . For example, ␤4-containing receptors tend to be more sensitive to mecamylamine than ␤2-containing receptors, regardless of the ␣ subunit. Likewise, ␣4-containing receptors tend to be more sensitive to DH␤E than ␣3-containing receptors, regardless of the ␤ subunit (Papke et al., 2008) .
Antagonism of nAChRs by Hexamethonium. Muscle, homomeric, and neuronal heteromeric mouse receptors were tested for sensitivity to inhibition by the putative ganglionic blocker hexamethonium (Fig. 6 ). As shown in Fig. 6A , the sensitivity of neuronal receptors to inhibition of peak currents by hexamethonium did not differ from that of muscletype receptors. In fact, the peak currents of ␣3␤2 receptors were 10-fold less sensitive to inhibition by hexamethonium than the peak currents of muscle receptors (Table 5) . However, for neuronal nAChR-mediated responses, the net charge was more potently inhibited by hexamethonium than the peak current responses (Fig. 6, C-F) , unlike the muscle receptor for which peak currents and net charge were inhibited similarly (Fig. 6B) . The disparity between the inhibition of peak currents and net charge was most striking for ␤2-containing receptors (Fig. 6 , D and F; see also raw data traces in Fig. 7 ).
Mechanistic Studies
Effects of Coapplication of Antagonist on ACh CRCs.
We conducted competition experiments with both hexamethonium and decamethonium on muscle nAChR and the two pairwise subunit combinations most likely related to ganglionic receptors, ␣3␤4 and ␣3␤2 receptors (Fig. 8) . The results, summarized in Table 6 , would suggest that the inhibition of ␣3␤2 receptors by decamethonium, and the inhibition of ␣1␤1ε␦ and ␣3␤2 receptors by hexamethonium, was noncompetitive, because there were changes in I max without significant changes in EC 50 . However, the inhibition of ␣3␤4 receptors by both drugs may be through both competitive and noncompetitive mechanisms.
Voltage Dependence. Because decamethonium and hexamethonium are charged molecules, if they inhibited nAChR function as channel blockers, binding to sites within the membrane electric field, then inhibition should be increased at more negative holding potentials. As shown in Fig. 9 , A and B, decamethonium produced significantly more inhibition of the ganglionic homologs ␣3␤2 and ␣3␤4 when the cells were voltage-clamped at Ϫ80 mV than when cells were voltageclamped at Ϫ40 mV.
Although the competition experiments suggested that the inhibition of muscle-type nAChR by hexamethonium was noncompetitive (Table 6 ), the inhibition did not appear to be voltage-dependent (Fig. 9, C and D) . In contrast, hexamethonium inhibition of the ganglionic homolog ␣3␤4 increased with hyperpolarization for measures of both peak current and net charge, whereas increased inhibition of ␣3␤2 receptors by hyperpolarization was apparent only for the net charge measurement.
Effects of ␣5 Coexpression with Pairwise Combination of Mouse Neuronal nAChR. The nicotinic ␣5 subunit is expressed in both the CNS and autonomic ganglia (Yu and Role, 1998; Kuryatov et al., 2008) . Although ␣5 will coassemble with other subunits, it is not believed to form either the primary or complementary face of ligand binding domains, but rather has been hypothesized to function as a "structural" subunit (Kuryatov et al., 2008) , like the ␤ subunit of muscle-type receptors. Because ␣5 is not required for function, it is sometimes difficult to confirm whether it does, in fact, coassemble with other functional subunits when it is coexpressed with them. Whether there are detectable effects of ␣5 coexpression may depend on the expression system used, or even the species origin of the clones being used. For example, the effects of ␣5 coexpression are readily detectable in oocytes when human clones are used (Kuryatov et al., 2008) , but not when rat clones are used (R. L. Papke, unpublished work) .
We coexpressed mouse ␣5 subunits with either mouse ␣3 and ␤4 subunits, mouse ␣3 and ␤2 subunits, or mouse ␣4 and ␤2 subunits and measured the ACh concentration response functions. As shown in Fig. 10 , ␣5 coexpression had marked effects on the responses of ␣3-containing receptors, but relatively little effect when coexpressed with ␣4 and ␤2 subunits. Coexpression of ␣5 with ␣3 and ␤4 did not affect ACh-evoked peak currents (Fig. 10, A and B) . However, net charge was affected by the addition of the ␣5 subunit, which abolished the two components evident for ␣3␤4 receptors, consistent with the hypothesis that for ␣3␤4 receptors ␣5 coexpression shifted the receptor population toward a single ␣5-containing form.
In the case of ␣3␤2 receptors, ␣5 coexpression altered both peak current and net charge. However, these CRCs remained at least as complex with the addition of the ␣5 subunit as with the absence of the subunit, suggesting that there may be an even more heterogeneous population of receptors with ␣5 subunit coexpression than there was without it. In addition, the responses of cells coexpressing ␣5 subunits with ␣3 and ␤2 subunits were generally very low, suggesting that ␣5 subunit expression may have limited the formation of functional receptors or ␣5-containing receptors have different activation properties, resulting in a low probability of being open.
The coexpression of ␣5 subunits with mouse ␣3␤2 and ␣3␤4 subunits also affected inhibition by decamethonium and hexamethonium. For ␣3␤2-containing receptors, ␣5 subunit coexpression reduced the potency of decamethonium, whereas for ␣3␤4-containing receptors ␣5 subunit coexpression increased the potency of both decamethonium and hexamethonium (Tables 4 and 5 ). In contrast, the coexpression of Activation and Inhibition of Mouse nAChR The control responses were relatively consistent throughout the entire range of test concentrations, and the data were normalized relative to the control responses to ACh applied alone. Data were calculated for both peak current and net charge. Each point is the average Ϯ S.E.M. of responses from at least four oocytes. A, the peak current results for all of the receptor subtypes. B-F, the results for both peak current and net charge for each of the receptor subtypes tested. B, ␣1␤1ε␦. C, ␣7. D, ␣4␤2. E, ␣3␤4. F, ␣3␤2.
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mouse ␣5 with mouse ␣4 and ␤2 subunits did not alter the IC 50 values (Tables 4 and 5 ) for inhibition by decamethonium and hexamethonium relative to cells expressing only ␣4 and ␤2 subunits (data not shown), suggesting that the ␣5 subunit was not being efficiently incorporated into ␣4␤2-containing receptors.
Effects of Coexpression of the Human ␤2-6-␣4 Concatamer with Human ␣4, ␤2, or ␣5 Subunits. Because the coexpression of ␣5 subunits had little effect on mouse receptors expressing ␣4 and ␤2 subunits, to further test the potential importance of ␣5 subunit coexpression on the inhibitory activity of hexamethonium and decamethonium experiments were conducted with linked human ␣4 and ␤2 subunits to generate receptors with fixed subunit composition . As reported, coexpression of the ␤2-6-␣4 construct with either monomeric ␤2, ␣4, or ␣5 subunits generates three distinct homogeneous receptor populations (Tapia et al., 2007) . The CRCs for ACh peak currents and net charge for these receptors are shown in Fig. 11 . Note that the HS ␣4(2)␤2(3) (Fig. 11A ) and ␣4(2)␤2(2)␣5 (Fig. 11C) receptors show a shift in the apparent potency of ACh for the net charge measure compared with the peak currents. The reason for this is that, although the peak currents of these receptors reach a maximal amplitude at relatively low ACh concentration, the HS receptors continue to respond as the agonist concentration decreases in the chamber, generating broad responses with progressively larger amounts of net charge (not shown). In contrast, the LS ␣4(3)␤2(2) receptors (Fig. 11B) require a higher ACh concentration to activate, and the responses decay rapidly as soon as the ACh concentration begins to decrease (not shown).
Coexpression of the ␤2-6-␣4 construct with monomeric ␤2, 
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␣4, or ␣5 subunits did not alter the effects of decamethonium on the receptors (Fig. 12) . However, the relative inhibition of net charge and peak current by hexamethonium was influenced by the expression of ␣5 subunits in place of either ␣4 or ␤2 subunits. The ␣5-containing receptors showed a decrease in the separation of the two inhibition curves to a point where there were no differences in the inhibition of net charge and peak currents, in contrast to the receptor subtypes containing only ␣4 and ␤2 subunits. A summary of the effects of the concatamers on ACh responses and inhibition by decamethonium and hexamethonium is presented in Table 7 .
Discussion
These studies provide an important reference for comparing mouse nAChR with published studies that have used receptors cloned from other species (Hussy et al., 1994; Zwart et al., 2006; Papke et al., 2008) . The ACh responses of mouse 
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nAChR are generally similar to those of human and rat receptors. The complex CRCs obtained with the pairwise expression of mouse neuronal ␣ and ␤ subunits support the hypothesis that the oocyte expression system allows the assembly of receptors with varying subunit composition and agonist sensitivity. In these studies this complexity was further revealed by the comparison of measures of peak current and net charge. These observations are also consistent with the complex concentration-response relationships obtained with native receptors from mouse brain (Grady et al., 2009 ). The ACh concentration-response studies for mouse ␣7 receptors are also consistent with what has been reported for ␣7 receptors of several other species (Papke, 2006) . Because the mouse is frequently used as a model for depression Rollema et al., 2009 ) and nicotine dependence (Picciotto et al., 1998) , it is important that these studies have confirmed the extent to which the pharmacology of cytisine and its derivatives varenicline and 3-pyr-Cyt are similar to what has been reported for the receptors from other species (Table 2) . However, it is also important to note the difference in the reversibility of the effects of varenicline on mouse receptors compared with rat 
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and human ␣4␤2 receptors. Varenicline is potent in mouse models of antidepressant activity (Rollema et al., 2009) , and, at least in part, this may be a reflection of the slow reversibility of its effects, which could lead to relatively large equilibrium desensitization of ␣4␤2 receptors in the mouse. However, it should also be noted that there are two functionally distinguishable genetic variants of the mouse ␣4 subunit that differ by a single amino acid at residue 529 (Dobelis et al., 2002; Kim et al., 2003) . The most common ␣4 variant in mice contains a threonine at this position, whereas the less common variant has an alanine. The experiments reported here used the common variant of ␣4 because it is the form of ␣4 found in C57BL/6 mice, the mouse strain most frequently used in research. Whether varenicline would have the same effect on ␣4␤2 nAChRs possessing the other variant of ␣4 remains to be determined. Regardless, the varenicline data would, at the very least, caution against straightforward translation of data from mice possessing the threonine variant of ␣4 to human therapeutics.
The results obtained with 3-pyr-Cyt, a compound shown to be efficacious in the mouse forced-swim model of depression , are consistent with the hypothesis that the efficacy of this compound involves inhibition rather than activation of ␣4␤2 receptors. This hypothesis is further supported by the observation that the nonselective nAChR antagonist mecamylamine is also effective in the forced-swim model.
Decamethonium continues to be used clinically as a muscle relaxant and experimentally as a pharmacological tool (Ball and Westhorpe, 2005) . Consistent with previous reports (Liu and Dilger, 1993) , we confirmed that decamethonium was a partial agonist for muscle receptors and had no agonist activity on any of the neuronal receptor subtypes tested. Our experiments therefore confirm the traditional classification of decamethonium as a selective depolarizing blocker of muscle-type nAChR (Paton and Zaimis, 1949) . With single-channel measurements of P open , which are effectively equivalent to measurement of net charge, Liu and Dilger (1993) estimated the efficacy of 100 M decamethonium to be only 2% that of ACh. We also estimated the efficacy of 100 M decamethonium to be approximately 2% the ACh maximum. Although decamethonium was a selective partial agonist on muscle-type receptors, it was nonetheless an effective antagonist of mouse neuronal nAChR, and particularly potent for inhibition of homomeric ␣7 receptors, compared with other subtypes (Table 4) .
Hexamethonium continues to be used as an experimental tool for distinguishing between the CNS and peripheral effects of nicotine and other cholinergic drugs (Andreasen et al., 2008) by comparing and contrasting its effects with those of mecamylamine. Because hexamethonium does not cross the blood-brain barrier, but mecamylamine does, hexamethonium blocks only the peripheral effects of nicotinic drugs.
Although hexamethonium is typically classified as a "ganglionic blocker " (Paton and Perry, 1953) , our data indicate that it showed no great selectivity for mouse ␣3-containing receptors that serve as models for ganglionic receptors. The inhibitory potency of hexamethonium for muscle-type receptors and ␣4␤2-type receptors, which serve as models for highaffinity receptors in the brain, was essentially comparable with its potency for inhibiting ␣3-containing receptors. This would suggest that perhaps the traditional classification of hexamethonium as a ganglionic blocker might have been caused by the functional protection of muscle and brain receptors in early whole-animal studies. The function of ␣4␤2 receptors in the brain would have been maintained by the exclusion of hexamethonium at the blood-brain barrier, whereas muscle function would have been protected by the large receptor reserve of the neuromuscular junction. Shown are the peak current and net charge data for human ␣4␤2 receptors with fixed subunit composition, formed by the coexpression of the linked ␤2 and ␣4 subunits (␤2-6-␣4 construct; Zhou et al., 2003) with monomeric ␤2 (A), ␣4 (B), or ␣5 (C). Data are expressed relative to the ACh maximal responses. Each point is the average Ϯ S.E.M. of responses from at least four oocytes. Although the inhibition of muscle-type receptors by decamethonium is clearly through a competitive mechanism, hexamethonium decreased the maximum responses of muscle receptors without change in the apparent EC 50 , suggesting a strictly noncompetitive mechanism. However, although the competition studies suggested noncompetitive inhibition of muscle-type receptors by hexamethonium, the inhibition was not voltage-dependent, which suggests that the site of binding of hexamethonium to muscle receptors was not within the electric field of the membrane.
Activation and Inhibition of Mouse nAChR
Differential effects on peak current amplitude and net charge measures provide insight into the mechanism of action and kinetics of inhibition (Neher and Steinbach, 1978; Jonsson et al., 2006) . The preferential inhibition of net charge compared with peak current is often indicative of use-dependent inhibition (Neher and Steinbach, 1978) . This trend was only strongly apparent for the inhibition of ␤2-containing receptors by hexamethonium (Figs. 5 and 6 ). In general, the data suggest that inhibition of all the neuronal receptors by either agent may have been caused by both competitive and noncompetitive activities.
The coexpression of ␣5 subunits with ␣3-containing receptors had functional effects, perhaps decreasing the receptor heterogeneity that was apparent when ␣3 and ␤4 subunits were expressed alone. Recent data with knockout mice have suggested that the majority of functional receptors in autonomic ganglia have ␣3␤4 subunit composition, sometimes coassembled with ␣5 (Wang et al., 2005) . Our data show that the ␣3␤4␣5 receptors had greater sensitivity to hexamethonium than did the other potential ganglionic models, ␣3␤4, ␣3␤2, and ␣3␤2␣5 (Table 5) . Interestingly, it has been reported that ␣5 knockout mice are more sensitive than wild type to cardiac blockade by hexamethonium (Wang et al., 2002) , suggesting that the knockout might have decreased the receptor reserve in the cardiac ganglia, indirectly increasing sensitivity to hexamethonium.
The use of linked subunits can provide improved control over the subunit composition of receptors formed in the oocyte expression system Kuryatov et al., 2008) . Because we have shown that the inhibitory activity of the novel antagonist 2,2,6,6-tetramethylpiperidin-4-yl heptanoate was strongly regulated by the presence or absence of the ␣5 subunit (Papke et al., 2005) , we used human ␤2-6-␣4 concatamers to achieve a controlled condition for the presence or absence of ␣5 subunits. The inhibitory activity of decamethonium was unaffected by ␣4, ␤2, or ␣5 in the position of the structural subunit. The potency for decamethonium inhibition of these human ␣4␤2-containing receptors was also not significantly different from its potency for inhibiting the mouse ␣4␤2 receptors (compare Tables 4 and 7) .
The primary effect of the inclusion of the ␣5 subunit in human ␣4␤2-containing receptors on inhibition by hexamethonium was to reduce the IC 50 values for peak current and net charge. This effect might have been caused by a change in the relative contributions of competitive and noncompetitive inhibitory activity.
The ultimate power of transgenic mouse models for human disease and therapeutics will have to rely on the translation of scientific results on multiple levels, in particular, at the molecular level. In this study we have demonstrated that mouse nicotinic receptor clones are an important model for human nAChR function, and we have identified the molecular properties of the three primary classes of receptors. This is one necessary step on the path that will bridge mouse disease models to the human conditions we desire to treat. As demonstrated by the difference in varenicline reversibility between human and mouse ␣4␤2 receptors, it may be dangerous to assume that any single expression system will be sufficient for predictive in vitro pharmacology. Comparisons between species are important at both the level of the intact organisms and the level of the single identified effector molecules. 
